Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Evofem Biosciences, Inc. - Common Stock
(OP:
EVFM
)
0.0120
+0.0001 (+0.84%)
Streaming Delayed Price
Updated: 3:35 PM EDT, Oct 29, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
544,289
Open
0.0124
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
0.0119
Today's Range
0.0113 - 0.0124
52wk Range
0.0061 - 0.0200
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MLNK, BFIN, MRCC, EVFM on Behalf of Shareholders
September 11, 2025
From
Halper Sadeh LLC
Via
GlobeNewswire
Evofem Revenue Jumps 16 Percent in Q2
August 14, 2025
Via
The Motley Fool
Performance
YTD
+25.0%
+25.0%
1 Month
-13.7%
-13.7%
3 Month
+25.0%
+25.0%
6 Month
+31.9%
+31.9%
1 Year
+13.2%
+13.2%
More News
Read More
TinyGemsBreaks – Aditxt Inc. (NASDAQ: ADTX) Appoints Evofem CEO Saundra Pelletier to Board of Directors
June 09, 2025
Via
Investor Brand Network
BioMedNewsBreaks — Aditxt Inc. (NASDAQ: ADTX) Appoints Evofem CEO Saundra Pelletier to Board of Directors
June 09, 2025
Via
Investor Brand Network
EVFM Stock Earnings: Evofem Biosciences Reported Results for Q2 2024
August 14, 2024
Via
InvestorPlace
Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials
December 12, 2024
From
Aditxt, Inc.
Via
Business Wire
Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares
November 08, 2024
From
Aditxt, Inc.
Via
Business Wire
BioMedNewsBreaks — Aditxt Inc. (NASDAQ: ADTX) Gains Support for Evofem Merger as Voting Agreements Secure Favorable Votes
November 06, 2024
Via
Investor Brand Network
Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem
November 06, 2024
From
Aditxt, Inc.
Via
Business Wire
Aditxt To Host Virtual Stakeholder Update and Q&A Session on Friday, November 1, 2024, at 11:30 AM Eastern Time
October 30, 2024
From
Aditxt, Inc.
Via
Business Wire
Sylvia Hermina Joins Aditxt’s Board of Directors, Elevating Leadership with Broader Perspectives
October 29, 2024
From
Aditxt, Inc.
Via
Business Wire
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Moves Closer to Evofem Acquisition with Final Investment Milestone
October 28, 2024
Via
Investor Brand Network
Aditxt Completes Final Equity Investment and Key Milestone Under the Amended and Restated Merger Agreement with Evofem
October 28, 2024
From
Aditxt, Inc.
Via
Business Wire
Aditxt to Host a Virtual Fireside Chat with Aditxt CEO Amro Albanna and Evofem CEO Saundra Pelletier, Moderated by MD & Media Personality Dr. Drew Pinsky, on October 28, 2024, at 11:30 AM Eastern Time
October 21, 2024
From
Aditxt, Inc.
Via
Business Wire
InvestorNewsBreaks – Aditxt (NASDAQ: ADTX), Evofem Announce Completion of Third Parent Equity Investment Under Amended Merger Agreement
October 08, 2024
Via
Investor Brand Network
InvestorNewsBreaks – Gaxos.ai Inc. (NASDAQ: GXAI) Announces Participation at the Upcoming Game Industry Conference
October 08, 2024
Via
Investor Brand Network
Aditxt Completes Third Parent Equity Investment Under Amended and Restated Merger Agreement With Evofem
October 08, 2024
From
Aditxt, Inc.
Via
Business Wire
InvestorNewsBreaks – Aditxt (NASDAQ: ADTX) Releases Shareholder Update, Plans for Remainder of 2024
October 03, 2024
Via
Investor Brand Network
Aditxt Delivers Shareholder Update and 2024 Year-End Plan
October 03, 2024
From
Aditxt, Inc.
Via
Business Wire
InvestorNewsBreaks – Aditxt (NASDAQ: ADTX) Acquisition Target Files Preliminary Proxy Seeking Stockholder Approval
September 24, 2024
Via
Investor Brand Network
Evofem Biosciences Files Preliminary Proxy for Stockholder Approval of the Acquisition by Aditxt
September 24, 2024
From
Aditxt, Inc.
Via
Business Wire
InvestorNewsBreaks – Aditxt (NASDAQ: ADTX) Subsidiary Signs Agreement with Evofem Biosciences Inc. (OTCQB: EVFM) Involving Unique Endometriosis Diagnostic Test
September 20, 2024
Via
Investor Brand Network
Aditxt’s Subsidiary Pearsanta to Collaborate with Evofem Biosciences for Targeted U.S. Launch of Endometriosis Diagnostic in Mid-2025
September 20, 2024
From
Aditxt, Inc.
Via
Business Wire
Aditxt and Evofem Sign Second Amendment to Amended and Restated Merger Agreement, Target Closing of Acquisition in Fourth Quarter of 2024
September 09, 2024
From
Aditxt, Inc.
Via
Business Wire
Aditxt to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 9th-11th, 2024
August 29, 2024
From
Aditxt, Inc.
Via
Business Wire
Frequently Asked Questions
Is Evofem Biosciences, Inc. - Common Stock publicly traded?
Yes, Evofem Biosciences, Inc. - Common Stock is publicly traded.
What exchange does Evofem Biosciences, Inc. - Common Stock trade on?
Evofem Biosciences, Inc. - Common Stock trades on the OTC Traded
What is the ticker symbol for Evofem Biosciences, Inc. - Common Stock?
The ticker symbol for Evofem Biosciences, Inc. - Common Stock is EVFM on the OTC Traded
What is the current price of Evofem Biosciences, Inc. - Common Stock?
The current price of Evofem Biosciences, Inc. - Common Stock is 0.0120
When was Evofem Biosciences, Inc. - Common Stock last traded?
The last trade of Evofem Biosciences, Inc. - Common Stock was at 10/29/25 03:35 PM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.